Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-Finding Study With Concomitant Evaluation of Safety and Efficacy.

Trial Profile

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-Finding Study With Concomitant Evaluation of Safety and Efficacy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Lenalidomide (Primary) ; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms RevliRit
  • Most Recent Events

    • 26 May 2012 Company added to the associations field as reported by European Clinical Trials Database record.
    • 09 May 2011 Planned end date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top